{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:23:24Z","timestamp":1773300204892,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.euf.2018.12.003","type":"journal-article","created":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T07:46:04Z","timestamp":1545551164000},"page":"155-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe"],"prefix":"10.1016","volume":"5","author":[{"given":"Annika","family":"Herlemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4339-6685","authenticated-orcid":false,"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2018.12.003_bib0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2018.12.003_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2018.12.003_bib0015","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.juro.2017.10.044","article-title":"Global, regional and national burden of prostate cancer, 0 to 2015: results from the Global Burden of Disease Study 2015","volume":"199","author":"Pishgar","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2018.12.003_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","article-title":"Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States","volume":"4","author":"Kelly","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2018.12.003_bib0025","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1002\/cncr.28932","article-title":"Expected population impacts of discontinued prostate-specific antigen screening","volume":"120","author":"Gulati","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2018.12.003_bib0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","article-title":"Increase in prostate cancer distant metastases at diagnosis in the United States","volume":"3","author":"Hu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2018.12.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2018.02.2734","article-title":"Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations","author":"Leyh-Bannurah","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.12.003_bib0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004\u20132013)","volume":"19","author":"Weiner","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2018.12.003_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2018.12.003_bib0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.6004\/jnccn.2018.0036","article-title":"NCCN guidelines updates: prostate cancer and prostate cancer early detection","volume":"16","author":"Carroll","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euf.2018.12.003_bib0055","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/RLU.0000000000000849","article-title":"18F-fluciclovine PET\/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET\/CT","volume":"40","author":"Nanni","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.euf.2018.12.003_bib0060","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"(68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography\/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2018.12.003_bib0065","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","article-title":"(68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review","volume":"36","author":"Corfield","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2018.12.003_bib0070","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2018.12.003_bib0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.prnil.2017.02.003","article-title":"(68)Ga-prostate-specific membrane antigen-positron emission tomography\/computed tomography in advanced prostate cancer: current state and future trends","volume":"5","author":"Udovicich","year":"2017","journal-title":"Prostate Int"},{"key":"10.1016\/j.euf.2018.12.003_bib0080","doi-asserted-by":"crossref","unstructured":"Futterer JJ, Surcel C, van den Bergh R, et al. Imaging modalities in synchronous oligometastatic prostate cancer. World J Urol. [In press] (epub ahead of print). https:\/\/doi.org\/10.1007\/s00345-018-2416-2.","DOI":"10.1007\/s00345-018-2416-2"},{"key":"10.1016\/j.euf.2018.12.003_bib0085","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/1754-9485.12791","article-title":"Comparative study between (68) Ga-prostate-specific membrane antigen positron emission tomography and conventional imaging in the initial staging of prostate cancer","volume":"62","author":"Wong","year":"2018","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.euf.2018.12.003_bib0090","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1464-410X.2011.10818.x","article-title":"Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC)","volume":"110","author":"Sartor","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.12.003_bib0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/bju.14489","article-title":"Management of patients with advanced prostate cancer in the Asia Pacific region: \u2018real-world\u2019 consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017","volume":"123","author":"Chiong","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.12.003_bib0100","article-title":"A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2018.12.003_bib0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bju.12937","article-title":"Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer","volume":"117","author":"Cooperberg","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.12.003_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/pcan.2012.23","article-title":"Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?","volume":"16","author":"Shore","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2018.12.003_bib0115","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S1470-2045(16)30491-0","article-title":"Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis","volume":"17","author":"Zhao","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2018.12.003_bib0120","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.euf.2018.12.003_bib0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bju.12764","article-title":"Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre\u2014impact on clinical decision-making and implications for patient inclusion","volume":"114","author":"Rao","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2018.12.003_bib0130","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2016.1196187","article-title":"Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review","volume":"12","author":"Syn","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918303833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456918303833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:47:46Z","timestamp":1762498066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456918303833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2405456918303833"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2018.12.003","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}